CathHELIX® – Novel Transcatheter Therapy for Mitral Valve Regurgitation
FACTS AND FIGURES
In the last decade, morbidity due to heart valve disease increased by more than 60 %. For people over 75, the increase was over 160 %, such that more than 10 % of this patient group are suffering from clinically relevant mitral valve disease.
The majority of mitral valve disease patients are not able to undergo treatments involving open heart surgery with cardiopulmonary bypass. CathHELIX® provides a new treatment option. This catheter-based mitral valve repair system has the potential to enable safer, faster, and considerably less traumatic cardiac interventions for mitral regurgitation patients worldwide, without compromising clinical efficacy.
One common sign of mitral valve disease is mitral valve leakage. However, primary mitral valve failure represents only a small proportion of patients suffering from mitral insufficiency (MI). The overwhelming majority suffer from functional mitral regurgitation (FMR).
FMR affects both the valve apparatus and the left ventricle. A treatment option is therefore vitally needed that not only prevents regurgitation, but is also able to stop (or even revert) the ventricular remodeling process.